Follistatin vs Setmelanotide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Follistatin
Follistatin is a glycoprotein that inhibits myostatin, the protein responsible for limiting muscle growth. By blocking myostatin, follistatin can theoretically allow for increased muscle development beyond natural limits.
Full details →Setmelanotide
Setmelanotide (Imcivree) is an FDA-approved MC4R agonist for chronic weight management in patients with obesity due to specific genetic conditions (POMC, PCSK1, or LEPR deficiency).
Full details →Side-by-Side Comparison
| Aspect | Follistatin | Setmelanotide |
|---|---|---|
| Dose Range | 50 mcg–100 mcg | 1 mg–3 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 2–4 weeks | 12–52 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to and neutralizes myostatin and activin, both of which are negative regulators of muscle mass. This removes the natural brake on muscle growth, allowing for enhanced hypertrophy. | Selective agonist of melanocortin 4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. |
| Typical Dosage | Research protocols typically use 100-300mcg daily, though optimal dosing is not well established. Gene therapy approaches have also been studied. | Adults: Start 2mg daily, titrate based on tolerability up to 3mg daily. Pediatrics (6+): Weight-based dosing starting at 1mg daily. |
| Administration | Subcutaneous injection. Different isoforms exist (FS344, FS315) with varying properties. Requires careful sourcing due to complexity. | Subcutaneous injection once daily. Requires genetic testing to confirm eligible mutations before prescribing. |
| Side Effects | Limited human data. Theoretical concerns about effects on other organs where activin signaling is important. | Injection site reactions, skin hyperpigmentation, spontaneous penile erections, depression, and suicidal ideation (boxed warning). GI effects less common than GLP-1s. |
| Best For |
Key Differences
Unique to Follistatin:
Unique to Setmelanotide:
Key Studies
Follistatin
- Heart to Heal: Unveiling Follistatin's Potential for Myocardial Regeneration.
Circulation research, 2025
- Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance.
Nature communications, 2025
- Follistatin drives neuropathic pain in mice through IGF1R signaling in nociceptive neurons.
Science translational medicine, 2024
Setmelanotide
- Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort.
Obesity (Silver Spring, Md.), 2026
- Setmelanotide for the Treatment of Acquired Hypothalamic Obesity.
The New England journal of medicine, 2026
- Impact of the Melanocortin-4 Receptor Agonist Setmelanotide on MASLD and Kidney Function in Bardet-Biedl Syndrome.
The Journal of clinical endocrinology and metabolism, 2026
Ready to Learn More?
Looking for trusted sources?